In a recent interview with Medsider, Dr. Sudhir Srivastava, founder, chairman and CEO of SS Innovations International Inc. (NASDAQ: SSII), outlined the company's strategy to broaden access to robotic surgery by prioritizing affordability and accessibility. Rather than directly competing with established platforms, SS Innovations aims to serve hospitals and patients that have historically been unable to adopt robotic surgery due to high equipment costs and operating expenses.
The SSi Mantra system, designed to reduce costs while supporting multiple specialties including cardiac surgery, is central to this strategy. The company has already installed more than 200 robotic systems and completed over 11,700 robotic procedures, including more than 170 telesurgeries. Telesurgery and teleproctoring are becoming key differentiators, enabling expert surgeons to support complex procedures remotely.
Artificial intelligence, automation, and new robotic platforms remain central to the company's long-term product roadmap. SS Innovations is pursuing regulatory approvals from the U.S. Food and Drug Administration (FDA) and European authorities while expanding into additional international markets. For investors evaluating emerging medical technology companies, understanding competitive advantages is as important as financial results, according to Dr. Srivastava.
The company's newsroom at https://ibn.fm/SSII provides the latest updates on SSII. The interview highlighted how SS Innovations is leveraging lower-cost technology, physician training, and remote surgical capabilities to democratize access to robotic surgery worldwide.
